+ All Categories
Home > Documents > Angiogenesis in Viral Immunoinflammatory Lesions

Angiogenesis in Viral Immunoinflammatory Lesions

Date post: 25-Jan-2016
Category:
Upload: asha
View: 21 times
Download: 0 times
Share this document with a friend
Description:
Angiogenesis in Viral Immunoinflammatory Lesions. Barry T. Rouse University of Tennessee Part 4. Does control of angiogenesis represent a smart approach to control stromal keratitis?. Problem: many factors to deal with. EMAP II Endothelial Monocyte Activating Polypeptide. - PowerPoint PPT Presentation
Popular Tags:
11
Angiogenesis in Viral Immunoinflammatory Lesions Barry T. Rouse University of Tennessee Part 4
Transcript
Page 1: Angiogenesis in Viral Immunoinflammatory Lesions

Angiogenesis in Viral Immunoinflammatory

Lesions

Barry T. RouseUniversity of Tennessee

Part 4

Page 2: Angiogenesis in Viral Immunoinflammatory Lesions

Does control of angiogenesis represent a smart approach to

control stromal keratitis?

• Problem: many factors to deal with

Page 3: Angiogenesis in Viral Immunoinflammatory Lesions

EMAP IIEndothelial Monocyte Activating Polypeptide

• Cytokine with several effects on neovascularization – Apoptosis of vascular endothelial cells– Upregulates TNF receptors – so TNF

induces apoptosis– Activates tissue factors and blood clots

• Proinflammatory effects• Rationale - targets growing blood

vessels so should inhibit effects of several angiogenic factors

Page 4: Angiogenesis in Viral Immunoinflammatory Lesions

0

10

20

30

40

0 10 100 1000

*

*

# o

f A

po

pto

tic

Cel

ls/H

PF

a

EMAP II (ng/ml)

Endo

Epi

Lim

b

EMAP II induces apoptosis in vascular endothelial cells in vitro and in vivo

Page 5: Angiogenesis in Viral Immunoinflammatory Lesions

0

5

10

15

20

An

gio

gen

esis

Sco

re

0 5 10 15 20 25

Days p.i.

Control

EMAP II

*

** *

*

c

i

ci

cc

cc

i

Control EMAP II

EMAP II suppresses neovascularization in murine HSK

D2 p.I.

D8 p.I.

D15 p.I.

Page 6: Angiogenesis in Viral Immunoinflammatory Lesions

HS

K L

esi

on

Sc

ore

0

1

2

3

4

5

0 5 10 15 20 25Days p.i.

Control

EMAP II

**

*

*

D8

D15

E FE FD15 D15

D15

D8Control EMAP II

EMAP II Suppresses HSK lesion score

Page 7: Angiogenesis in Viral Immunoinflammatory Lesions

Future approaches – possible siRNA targetingtargeting

multiple angiogenesis factors

Page 8: Angiogenesis in Viral Immunoinflammatory Lesions

Preliminary studyPreliminary study

• Plasmid encoding siRNA expressed following Plasmid encoding siRNA expressed following intra-stromal or sub-conjunctival injectionintra-stromal or sub-conjunctival injection

• Mixture of siRNA inhibiting VEGF and VEGF Mixture of siRNA inhibiting VEGF and VEGF receptors gave significant inhibition of receptors gave significant inhibition of

angiogenesis induced by CpGangiogenesis induced by CpG

Page 9: Angiogenesis in Viral Immunoinflammatory Lesions

Inhibition of CpG induced angiogenesis by siRNA delivery

CpG + siLacZ Day 4 CpG + siVEGF, R1, R2 Day 4

Page 10: Angiogenesis in Viral Immunoinflammatory Lesions

General Conclusions

• Herpes induced stromal keratitis an immunoinflammatory lesion

• Neovascularization a major step in pathogenesis

• HSV induces angiogenesis indirectly• Control of angiogenesis inhibits SK• Need multiple approaches for

satisfactory therapy

Page 11: Angiogenesis in Viral Immunoinflammatory Lesions

Colleagues Involved

• Dennis Klinman

• Margaret Schwartz

• Napoleone Ferrara

• Mei Zheng

• Bum-Seok Kim

• Kaustuv Banerjee

• Partha Biswas

• Sujin Lee


Recommended